Sequent Scientific Limited
NSE: SEQUENT BSE: SEQUENT
NSE
145.62
4.15 (2.93%)
Prev Close
141.47
Open Price
140.99
Volume
484,611
Today Low / High
137.55 / 147.34
52 WK Low / High
92.05 / 240.7
Range
138 - 153
BSE
146.25
4.85 (3.43%)
Prev Close
141.4
Open Price
141.4
Volume
16,743
Today Low / High
137.6 / 147.2
52 WK Low / High
91.85 / 240.9
Range
139 - 154
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 145.62 (target range: 138 - 153), reflecting a change of 4.15 (2.93348%). On the BSE, it is listed at 146.25 (target range: 139 - 154), showing a change of 4.85 (3.42999%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
04 Mar
140.99
3.12%
03 Mar
148.50
-4.73%
28 Feb
146.80
1.23%
27 Feb
157.00
-3.75%
25 Feb
156.12
0.86%
24 Feb
155.51
0.39%
21 Feb
157.75
1.12%
20 Feb
149.50
6.16%
19 Feb
145.00
3.50%
18 Feb
148.50
-0.48%
17 Feb
146.52
2.90%
14 Feb
157.50
-6.97%
13 Feb
154.39
2.15%
12 Feb
150.80
0.62%
11 Feb
156.58
-3.01%
10 Feb
161.00
-2.75%
07 Feb
163.02
-3.02%
06 Feb
167.88
-2.89%
05 Feb
165.88
-0.92%
04 Feb
162.88
0.53%
Sequent Scientific Limited Graph
Sequent Scientific Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking Target Price for Sequent Scientific Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 146, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 146.25 | 147.71 | 132.94 - 162.48 |
| 149.18 | 119.34 - 179.01 | ||
| 150.64 | 105.45 - 195.83 | ||
| Bearish Scenario | 146.25 | 144.79 | 130.31 - 159.27 |
| 143.33 | 114.66 - 171.99 | ||
| 141.86 | 99.30 - 184.42 |
Overview of Sequent Scientific Limited
ISIN
INE807F01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
425,555
Market Cap
36,448,977,240
Last Dividend
0
Official Website
IPO Date
2016-03-10
DCF Diff
141.12
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of SEQUENT
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-09-08 | September 08, 21 | 0.5 | 0.5 | 2021-09-10 | 2021-10-21 | |
| 2019-08-21 | August 21, 19 | 0.2 | 0.2 | 2019-08-22 | 2019-09-28 | 2019-05-14 |
| 2017-11-20 | November 20, 17 | 0.2 | 0.2 | 2017-11-21 | 2017-12-04 | 2017-11-09 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,366.30 Cr | 785.26 Cr | 581.04 Cr | 0.4253 | 0.00 Cr | 55.36 Cr | 37.02 Cr | -35.87 Cr | -1.44 | 54.98 Cr | -0.0263 |
| 2023-03-31 | 1,420.91 Cr | 833.77 Cr | 587.14 Cr | 0.4132 | 0.00 Cr | 54.03 Cr | -15.35 Cr | -121.16 Cr | -4.88 | -46.45 Cr | -0.0853 |
| 2022-03-31 | 1,410.17 Cr | 844.44 Cr | 565.74 Cr | 0.4012 | 0.00 Cr | 50.03 Cr | 57.96 Cr | 40.96 Cr | 1.67 | 120.25 Cr | 0.0290 |
| 2021-03-31 | 1,352.04 Cr | 736.56 Cr | 615.47 Cr | 0.4552 | 0.00 Cr | 45.51 Cr | 168.76 Cr | 95.44 Cr | 3.87 | 211.61 Cr | 0.0706 |
| 2020-03-31 | 1,160.51 Cr | 638.41 Cr | 522.10 Cr | 0.4499 | 0.00 Cr | 38.05 Cr | 125.23 Cr | 69.91 Cr | 2.87 | 180.41 Cr | 0.0602 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 64.81 Cr | 1,540.38 Cr | 827.43 Cr | 656.5600 Cr | 487.69 Cr | 422.88 Cr | 346.23 Cr | 311.23 Cr | 8.13 Cr | 0.00 Cr | 0.01 Cr | 626.9900 Cr |
| 2023-03-31 | 41.57 Cr | 1,529.12 Cr | 779.93 Cr | 698.7781 Cr | 443.60 Cr | 402.02 Cr | 346.09 Cr | 352.13 Cr | 33.84 Cr | 21.47 Cr | 0.01 Cr | 526.0659 Cr |
| 2022-03-31 | 57.50 Cr | 1,441.50 Cr | 701.08 Cr | 692.4070 Cr | 364.90 Cr | 307.40 Cr | 347.97 Cr | 325.34 Cr | 39.72 Cr | 17.99 Cr | 36.79 Cr | 512.1210 Cr |
| 2021-03-31 | 53.74 Cr | 1,392.56 Cr | 616.24 Cr | 727.6510 Cr | 276.08 Cr | 222.33 Cr | 264.36 Cr | 347.86 Cr | 81.25 Cr | 8.44 Cr | 76.94 Cr | 460.9040 Cr |
| 2020-03-31 | 68.10 Cr | 1,518.30 Cr | 730.81 Cr | 742.7600 Cr | 391.37 Cr | 323.27 Cr | 219.42 Cr | 355.95 Cr | 51.02 Cr | 48.08 Cr | 131.29 Cr | 469.5990 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 30.5950 Cr | -11.9050 Cr | 4.5460 Cr | -0.2120 Cr | 23.2360 Cr | 64.8100 Cr | -30.8070 Cr | -35.8690 Cr | 54.8070 Cr | 0.0000 Cr | 0.2860 Cr |
| 2023-03-31 | 16.8080 Cr | -64.9580 Cr | 32.2280 Cr | -69.3710 Cr | -15.9220 Cr | 41.5740 Cr | -86.1790 Cr | -137.6590 Cr | 12.3490 Cr | 0.0000 Cr | 5.0790 Cr |
| 2022-03-31 | 30.5950 Cr | -95.5660 Cr | 67.2570 Cr | -1.8690 Cr | 3.7520 Cr | 57.4960 Cr | -32.4640 Cr | 53.3860 Cr | 31.3120 Cr | -12.3440 Cr | -114.7330 Cr |
| 2021-03-31 | 114.7540 Cr | 9.6480 Cr | -138.7540 Cr | 61.9240 Cr | -14.3520 Cr | 53.7440 Cr | -52.8300 Cr | 145.4520 Cr | -117.4150 Cr | 0.0000 Cr | -45.6170 Cr |
| 2020-03-31 | 115.3300 Cr | -72.2700 Cr | -42.7530 Cr | 74.6080 Cr | 0.3070 Cr | 68.0960 Cr | -40.7220 Cr | 94.0750 Cr | -6.7720 Cr | -5.8260 Cr | -19.3140 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 390.81 Cr | 202.53 Cr | 188.28 Cr | 0.4818 | 0.00 Cr | 3.44 Cr | 0.14 | 40.03 Cr | 0.0088 |
| 2024-09-30 | 368.65 Cr | 195.29 Cr | 173.36 Cr | 0.4703 | 19.47 Cr | 2.61 Cr | 0.11 | 39.29 Cr | 0.0071 |
| 2024-06-30 | 390.21 Cr | 292.59 Cr | 97.62 Cr | 0.2502 | 113.87 Cr | 6.51 Cr | 0.26 | 42.73 Cr | 0.0167 |
| 2024-03-31 | 361.20 Cr | 273.21 Cr | 87.99 Cr | 0.2436 | 17.77 Cr | -0.91 Cr | -0.04 | 31.56 Cr | -0.0025 |
| 2023-12-31 | 329.36 Cr | 253.95 Cr | 75.41 Cr | 0.2290 | 7.44 Cr | 8.27 Cr | 0.33 | 22.89 Cr | 0.0251 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 68.05 Cr | 7.38 Cr | 75.43 Cr | 0.00 Cr | 361.48 Cr | 828.95 Cr | 306.00 Cr | 1,562.05 Cr | 820.18 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 72.44 Cr | 0.00 Cr | 0.00 Cr | 72.44 Cr | 0.00 Cr | 0.00 Cr | -712.96 Cr |
| 2024-03-31 | 69.83 Cr | 2.61 Cr | 72.44 Cr | 335.63 Cr | 346.23 Cr | 810.94 Cr | 311.23 Cr | 1,540.38 Cr | 827.43 Cr |
| 2023-12-31 | -59.88 Cr | 119.76 Cr | 59.88 Cr | 0.00 Cr | 0.00 Cr | 59.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 58.86 Cr | 2.96 Cr | 61.82 Cr | 309.46 Cr | 326.17 Cr | 772.89 Cr | 335.51 Cr | 1,500.95 Cr | 818.29 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 6.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -0.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 8.27 Cr | 30.91 Cr | 0.00 Cr | 0.00 Cr | 30.91 Cr | 89.84 Cr | 58.93 Cr | 0.00 Cr | 30.91 Cr |
| 2023-09-30 | -8.38 Cr | 30.72 Cr | 0.00 Cr | 0.00 Cr | 30.72 Cr | 58.93 Cr | 28.21 Cr | 0.00 Cr | 30.72 Cr |
| 2023-06-30 | -34.85 Cr | 28.48 Cr | 0.00 Cr | 0.00 Cr | 28.48 Cr | 70.23 Cr | 41.75 Cr | 0.00 Cr | 28.48 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,558.65 | ₹3,739,637,772,000.00 | ₹781,719.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,506.25 | ₹1,461,738,681,250.00 | ₹64,908.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹2,949.60 | ₹998,277,372,000.00 | ₹166,276.00 |
| Mankind Pharma Limited | MANKIND | ₹2,291.25 | ₹945,320,533,950.00 | ₹177,711.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,114.75 | ₹928,700,476,795.00 | ₹434,095.00 |
| Lupin Limited | LUPIN | ₹1,934.60 | ₹883,108,142,600.00 | ₹259,741.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹870.20 | ₹875,621,346,000.00 | ₹343,556.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.85 | ₹610,335,781,700.00 | ₹413,280.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,591.20 | ₹548,946,828,000.00 | ₹17,608.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,313.55 | ₹370,668,047,400.00 | ₹97,865.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,339.40 | ₹339,811,137,600.00 | ₹56,310.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,451.70 | ₹306,246,750,400.00 | ₹61,223.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,161.90 | ₹295,779,073,500.00 | ₹165,600.00 |
| Laurus Labs Limited | LAURUSLABS | ₹541.60 | ₹292,059,424,800.00 | ₹1,255,902.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,614.85 | ₹251,280,349,100.00 | ₹29,467.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,238.20 | ₹201,165,401,200.00 | ₹280,998.00 |
| Piramal Enterprises Limited | PEL | ₹877.00 | ₹197,744,206,000.00 | ₹172,994.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹7,180.00 | ₹179,500,000,000.00 | ₹18,235.00 |
| Eris Lifesciences Limited | ERIS | ₹1,181.00 | ₹160,768,349,000.00 | ₹22,410.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹775.65 | ₹152,464,090,950.00 | ₹312,147.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹917.85 | ₹146,196,065,850.00 | ₹70,165.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹11,307.10 | ₹145,068,962,290.00 | ₹40,103.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹801.90 | ₹143,628,309,000.00 | ₹553,341.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,794.05 | ₹136,368,790,385.00 | ₹351,707.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹474.45 | ₹115,051,278,300.00 | ₹761,172.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,120.00 | ₹84,988,928,000.00 | ₹2,119.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹733.60 | ₹66,483,240,936.00 | ₹180,483.00 |
| FDC Limited | FDC | ₹380.40 | ₹61,932,924,000.00 | ₹76,550.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹623.30 | ₹60,953,067,970.00 | ₹158,952.00 |
| Strides Pharma Science Limited | STAR | ₹606.80 | ₹55,924,326,360.00 | ₹175,466.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹912.85 | ₹46,298,930,435.00 | ₹61,199.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹630.35 | ₹44,380,296,030.00 | ₹15,929.00 |
| Hikal Limited | HIKAL | ₹353.10 | ₹43,537,583,100.00 | ₹104,019.00 |
| Innova Captab Limited | INNOVACAP | ₹676.60 | ₹38,718,387,638.00 | ₹65,536.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹117.03 | ₹37,978,809,660.00 | ₹840,880.00 |
| Sequent Scientific Limited | SEQUENT | ₹145.38 | ₹36,388,904,760.00 | ₹484,563.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,080.00 | ₹34,401,120,000.00 | ₹13,355.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹316.20 | ₹31,707,903,600.00 | ₹60,257.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹346.80 | ₹31,652,436,000.00 | ₹50,219.00 |
| Suven Life Sciences Limited | SUVEN | ₹116.15 | ₹25,329,295,100.00 | ₹387,876.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹45.64 | ₹25,008,620,560.00 | ₹2,413,022.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹469.75 | ₹23,648,166,244.00 | ₹100,544.00 |
| Alembic Limited | ALEMBICLTD | ₹89.77 | ₹23,051,320,050.00 | ₹318,318.00 |
| Indoco Remedies Limited | INDOCO | ₹226.93 | ₹20,933,815,947.00 | ₹228,598.00 |
| Bajaj HealthCare Limited | BAJAJHCARE | ₹635.05 | ₹20,056,974,665.00 | ₹289,638.00 |
Key Executives
Chief Financial Officer
Mr. Saurav Bhala
Gender: male
Year Born:
Assoc. Vice President, Head of Legal & Chief Risk Officer
Mr. Phillip Trott
Gender: male
Year Born:
Company Secretary & Compliance Officer
Ms. Yoshita Vora
Gender: female
Year Born:
Executive Director
Mr. Vedprakash Ragate
Gender: male
Year Born:
Corporate Vice President of Ra Qa and Technical Services
Mr. Ramesh Kumar Pillai
Gender: male
Year Born: 1965
Head of Investor Relations
Mr. Abhishek Singhal
Gender: male
Year Born:
Vice President of HR & Administration
Mr. Prasad Lad
Gender: male
Year Born:
Executive Vice President of Human Resources & Administration
Mr. Ravi Nair
Gender: male
Year Born:
MD, Chief Executive Officer & Director
Mr. Rajaram Narayanan
Gender: male
Year Born: 1968
FAQs about Sequent Scientific Limited
Who is the CEO of the company?
The CEO is Mr. Rajaram Narayanan.
What is the current market price of the stock?
The current price is ₹145.62.
What is the 52-week price range?
The range is ₹92.05-240.7.
What is the market capitalization of the company?
The market capitalization is ₹3,644.90 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 307.16.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Sequent Scientific Limited (ISIN: INE807F01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,644.90 crores and an average daily volume of 425,555 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.